Information de reference pour ce titreAccession Number: | 00004872-201712000-00003.
|
Author: | Cuspidi, Cesare a,b; Dell'Oro, Raffaella a; Sala, Carla c; Tadic, Marijana d; Gherbesi, Elisa c; Grassi, Guido a,e; Mancia, Giuseppe b
|
Institution: | (a)Department of Health Science, University of Milano-Bicocca, Milan (b)Istituto Auxologico Italiano, Meda (c)Department of Medicine and Surgery, Fondazione Ospedale Maggiore Policlinico di Milano, University of Milano, Milan, Italy (d)Department of Cardiology, Charite-University-Medicine Campus Virchow Klinikum, Berlin, Germany (e)Istituto di Ricerche a Carattere Scientifico Multimedica, Sesto San Giovanni, Milan, Italy
|
Title: | |
Source: | Journal of Hypertension. 35(12):2339-2345, December 2017.
|
Abstract: | Aim: Data on left ventricular hypertrophy (LVH) in patients with renal artery stenosis (RAS) and its regression following renal revascularization are scanty. We performed a meta-analysis to provide comprehensive information on this clinically relevant issue.
Methods: Full articles providing data on: LVH, as assessed by echocardiography, in RAS patients as compared with essential hypertensive counterparts; changes of left ventricular (LV) mass index after renal artery revascularization were considered.
Results: A total of 905 study participants (RAS = 446, essential hypertensive = 459) of both sex were included in nine studies. Pooled LV mass index was higher in RAS than in essential hypertensive patients (140.4 +/- 11.1 g/m2 versus 121.8 +/- 6.2 g/m2, standard mean difference being 0.41 +/- 0.07 [95% confidence interval (CI) 0.27-0.51, P < 0.001]. Among 360 RAS patients undergone renal revascularization from eight studies, baseline and post-intervention pooled mean LV mass index values were 129.0 +/- 10.2 g/m2 and 115.5 +/- 9.9 g/m2, respectively, the standard mean difference being-0.36 +/- 0.06 (95% CI from -0.47 to -0.25, P < 0.001). These findings were unaffected by publication bias or single study effect.
Conclusion: Our meta-analysis indicates that RAS patients have an increased likelihood of LVH compared with essential hypertensive counterparts and renal artery revascularization has a beneficial effect on LV structure, as reflected by a significant decrease in LV mass index.
Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | hypertension; left ventricular hypertrophy; renal artery stenosis.
|
References: | 1. Cuspidi C, Sala C, Casati A, Bombelli M, Grassi G, Mancia G. Clinical and prognostic value of hypertensive cardiac damage in the PAMELA Study. Hypertens Res 2017; 40:329-335.
2. Kotsis V, Stabouli S, Toumanidis S, Tsivgoulis G, Rizos Z, Trakateli C, et al. Obesity and daytime pulse pressure are predictors of left ventricular hypertrophy in true normotensives individuals. J Hypertens 2010; 28:1065-1073.
3. Gidding SS, Liu K, Colangelo LA, Cook NL, Goff DC, Glasser SP, et al. Longitudinal determinants of left ventricular mass and geometry: the coronary artery risk development in young adults (CARDIA) study. Circ Cardiovasc Imaging 2013; 6:769-775.
4. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16:1031-1041.
5. Catena C, Colussi G, Valeri M, Sechi LA. Association of aldosterone with left ventricular mass: interaction with plasma fibrinogen levels. Am J Hypertens 2013; 26:111-117.
6. Mascolo A, Sessa M, Scavone C, De Angelis A, Vitale C, Berrino L, et al. New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): focus on cardiovascular and neurological diseases. Int J Cardiol 2017; 227:734-742.
7. Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease role of the renin-angiotensin-aldosterone system. Med Clin N Am 2004; 88:83-97.
8. Munoz-Durango N, Fuentes CA, Castillo AE, Gonzalez-Gomez LM, Vecchiola A, Fardella CE, Kalergis AM. Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. Int J Mol Sci 2016; 17:
9. Textor SC. Renal arterial disease and hypertension. Med Clin North Am 2017; 101:65-79.
10. Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis 2016; 10:162-171.
11. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89:3A-9A.
12. Ferrario CM, Strawn WB. Role of the Renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98:121-128.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
14. Vensel LA, Devereux RB, Pickering TG, Herrold EM, Borer JS, Laragh JH. Cardiac structure and function in renovascular hypertension produced by unilateral and bilateral renal artery stenosis. Am J Cardiol 1986; 58:575-582.
15. Yoshihara F, Nishikimi T, Yoshitomi Y, Nakasone I, Abe H, Matsuo H, Omae T. Left ventricular structural and functional characteristics in patients with renovascular hypertension, primary aldosteronism and essential hypertension. Am J Hypertens 1996; 9:523-528.
16. Losito A, Selvi A, Jeffery S, Afzal AR, Parente B, Cao PG. Angiotensin-converting enzyme gene I/D polymorphism and carotid artery disease in renovascular hypertension. Am J Hypertens 2000; 13:128-133.
17. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998; 32:985-992.
18. Iantorno M, Pola R, Schinzari F, Filice G, Mettimano M, Cardillo C, Melina D. Association between altered circadian blood pressure profile and cardiac end-organ damage in patients with renovascular hypertension. Cardiology 2003; 100:114-119.
19. Wright JR, Shurrab AE, Cooper A, Kalra PR, Foley RN, Kalra PA. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol 2005; 16:2746-2753.
20. Zeller T, Rastan A, Schwarzwalder U, Muller C, Frank U, Burgelin K, et al. Regression of left ventricular hypertrophy following stenting of renal artery stenosis. J Endovasc Ther 2007; 14:189-197.
21. Khangura KK, Eirin A, Kane GC, Misra S, Textor SC, Lerman A, Lerman LO. Cardiac function in renovascular hypertensive patients with and without renal dysfunction. Am J Hypertens 2014; 27:445-453.
22. Hoshida S, Shinoda Y, Inui H, Hosoi R, Teranishi F, Asaoka N, et al. Difference in left ventricular mass index between hypertensive patients with and without renal artery stenosis by propensity score analysis. J Clin Hypertens (Greenwich) 2014; 16:606-611.
23. Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma and pheocromocitoma. Am J Hypertens 1993; 6:907-913.
24. Yoshitomi Y, Nishikimi T, Abe H, Yoshiwara F, Suzuki T, Ashizawa A, et al. Comparison of changes in cardiac structure after treatment in secondary hypertension. Hypertension 1996; 27:319-323.
25. Symonides B, Chodakowska J, Januszewicz A, Lapinski M, Januszewicz M, Rowinski O, et al. Effects of the correction of renal artery stenosis on blood pressure, renal function and left ventricular morphology. Blood Press 1999; 8:141-150.
26. Lekston A, Niklewski T, Gasior M, Chudek J, Wilczek K, Wiecek A, et al. Effects of short and long-term efficacy of percutaneous transluminal renal angioplasty with or without intravascular brachytherapy on regression of left ventricular hypertrophy in patients with renovascular hypertension. Pol Arch Med Wewn 2009; 119:211-218.
27. Corriere MA, Hoyle JR, Craven TE, D'Agostino RB, Edwards MS, Moore PS, Hansen KJ. Changes in left ventricular structure and function following renal artery revascularization. Ann Vasc Surg 2010; 24:80-84.
28. Marcantoni C, Zanoli L, Rastelli S, Tripepi G, Matalone M, Mangiafico S, et al. Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. Am J Kidney Dis 2012; 60:39-46.
29. Rzeznik D, Przewlocki T, Kablak-Ziembicka A, Roslawiecka A, Kozanecki A, Lach J, Podolec P. Impact of renal artery stenting on cytokine levels, left ventricle mass and diastolic function. Kardiol Pol 2013; 71:121-128.
30. Devereux RB, Reickek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55:613-618.
31. Safian RD, Madder RD. Refining the approach to renal artery revascularization. JACC Cardiovasc Interv 2009; 2:161-174.
32. Edwards MS, Hansen KJ, Craven TE, Bleyer AJ, Burke GL, Levy PJ, Dean RH. Associations between renovascular disease and prevalent cardiovascular disease in the elderly: a population-based study. Vasc Endovascular Surg 2004; 38:25-35.
33. Khosla S, Kunjummen B, Manda R, Khaleel R, Kular R, Gladson M, et al. Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Catheter Cardiovasc Interv 2003; 58:400-403.
34. Kadian-Dodov D, Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi YW, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U.S. Registry for FMD. J Am Coll Cardiol 2016; 68:176-185.
35. Peng M, Jiang XJ, Dong H, Zou YB, Zhang HM, Song L, et al. Etiology of renal artery stenosis in 2047 patients: a single-center retrospective analysis during a 15-year period in China. J Hum Hypertens 2016; 30:124-128.
36. Losito A, Fagugli RM, Zampi I, Parente B, de Rango P, Giordano G, Cao P. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens 1996; 9:1062-1067.
37. Wu S, Polavaru N, Stouffer GA. Left ventricular hypertrophy in patients with renal artery stenosis. Am J Med Sci 2006; 332:334-338.
38. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54:1084-1091.
39. Iwashima Y, Fukuda T, Kusunoki H, Hayashi SI, Kishida M, Yoshihara F, et al. Effects of percutaneous transluminal renal angioplasty on office and home blood pressure and home blood pressure variability in hypertensive patients with renal artery stenosis. Hypertension 2017; 69:109-117.
40. Koivuviita N, Tertti R, Luotolahti M, Raitakari Q, Vahlberg T, Nuutila P, et al. The effect of revascularization of atherosclerotic renal artery stenosis on coronary flow reserve and peripheral endothelial function. Nephron Clin Pract 2011; 118:c241-c248.
|
Language: | English.
|
Document Type: | REVIEWS.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0263-6352
|
NLM Journal Code: | iew, 8306882
|
DOI Number: | https://dx.doi.org/10.1097/HJH.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|